Evidence map›Paper›PMID 42305132›Full record

ArticleBio-protocol2026

In-Culture Antibody Capture Using Transient CHO Expression Systems.

Jing Zhou, Lauren Gebhardt, Molica Abel, Audrey Vogt, Bo Hee Shin, Ana Santos, Jerome Puginier, Florian M Wurm, Maria J Wurm, Sarah L Herrick-Wagman and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bio-protocol, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Jing ZhouBioMedicine Design, Preclinical and Translational Sciences, Pfizer Research and Development, Cambridge, MA, USA.
Lauren GebhardtBioMedicine Design, Preclinical and Translational Sciences, Pfizer Research and Development, Cambridge, MA, USA.
Molica AbelBioMedicine Design, Preclinical and Translational Sciences, Pfizer Research and Development, Cambridge, MA, USA.
Audrey VogtBioMedicine Design, Preclinical and Translational Sciences, Pfizer Research and Development, Cambridge, MA, USA.
Bo Hee ShinBioMedicine Design, Preclinical and Translational Sciences, Pfizer Research and Development, Cambridge, MA, USA.
Ana SantosMagellanBiologics, Parque Tecnológico de Cantanhede Edifício III Laboratório 5, Cantanhede, Portugal.
Jerome PuginierMagellanBiologics, Parque Tecnológico de Cantanhede Edifício III Laboratório 5, Cantanhede, Portugal.
Florian M WurmMagellanBiologics, Parque Tecnológico de Cantanhede Edifício III Laboratório 5, Cantanhede, Portugal.
Maria J WurmMagellanBiologics, Parque Tecnológico de Cantanhede Edifício III Laboratório 5, Cantanhede, Portugal.
Sarah L Herrick-WagmanBioMedicine Design, Preclinical and Translational Sciences, Pfizer Research and Development, Cambridge, MA, USA.
Adedolapo AdeniyiBioMedicine Design, Preclinical and Translational Sciences, Pfizer Research and Development, Cambridge, MA, USA.
Guoying Grace YanBioMedicine Design, Preclinical and Translational Sciences, Pfizer Research and Development, Cambridge, MA, USA.
Sean LimBioMedicine Design, Preclinical and Translational Sciences, Pfizer Research and Development, Cambridge, MA, USA.
Laura LinBioMedicine Design, Preclinical and Translational Sciences, Pfizer Research and Development, Cambridge, MA, USA.
Aaron M D'AntonaBioMedicine Design, Preclinical and Translational Sciences, Pfizer Research and Development, Cambridge, MA, USA.
Xiaotian ZhongBioMedicine Design, Preclinical and Translational Sciences, Pfizer Research and Development, Cambridge, MA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antibody therapeutics have demonstrated transformative impacts on improving the quality of life of millions of patients, whereas advances in antibody discovery technologies have imposed a significant production challenge for the generation of a large diversity of therapeutic antibody candidates. A demand for the rapid production of dozens of purified antibodies in 10-mg quantities is entailed for functional screening and molecular assessment studies. Here, we present a robust semi-automated production protocol that bridges the gap between miniaturized high-throughput screenings and conventional custom-scale workflows. This methodology and workflow utilize a simple high-titer transient Chinese hamster ovary (CHO) cell host-CHO4Tx

Indexed as

AmMagTM Protein-A magnetic beadsCHO4Tx®GenScript AmMagTM SA-PlusIn-culture antibody capturingSemi-automation purificationTransient gene expression

Identifiers

PMID42305132
PMCPMC13266610

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.